Modern develops single dose of booster against COVID-19 and flu

by

New York. The American pharmaceutical company Moderna announced on Thursday that it has begun a program to develop a single-dose vaccine that combines a booster against covid-19 and another against the flu.

“Today we announce the first step in our new respiratory vaccine program for the development of a single-dose vaccine that combines a covid-19 booster and a flu booster,” the company said in a statement.

The company made this announcement in a note in which it presented the advances of its product portfolio.

Moderna delivered the first results of its clinical trials last week to health and European authorities for the evaluation of a third dose of booster against covid 19 with the aim of obtaining its authorization.

  1. More people are being vaccinated against COVID-19 in Puerto Rico

  2. Puerto Rico makes daylight with another 18 killed by COVID-19

“We are pleased to have applied for a conditional marketing authorization from the European Medicines Agency for our (vaccine) booster at the 50 microgram dose level,” the pharmaceutical company said in a statement. American last Friday, after applying for permission in Europe.

Moderna CEO Stéphane Bancel has pointed out that additional studies and analyzes “show that a booster dose of 50 micrograms” of his covid-19 vaccine “provokes strong antibody responses against the Delta variant”.

The company explained that the second phase of the clinical study was modified to include the third dose administered “approximately” 6 months after the second.

In August, the FDA began recommending the use of a third dose for people with a weakened immune system, such as organ transplant patients, people with HIV, or some cancer patients, who did not go record an adequate immune response to the first two vaccines.

Recently, US authorities also announced plans to begin offering the booster dose to the general population who have received mRNA vaccines (Modern and Pfizer) starting the week of September 20 for those who have been given the two initial doses more than eight months ago.

This, however, has yet to be approved by the FDA and the country’s Centers for Disease Control and Prevention (CDC).

.Source